Pre-diagnostic high-sensitive @entity1851 and XXXX risk, recurrence, and survival.

@entity1 @entity32 @entity0 @entity1851
UNASSIGNED: Inflammation may initiate and promote @entity0 development, and be associated with elevated circulating levels of @entity32 markers. A total of eight 130 initially healthy @entity1 , participated in the population-based Troms   study (1994-2008). Pre-diagnostic high-sensitivity @entity1851 (hs-CRP) was assessed. During 14.6  years of follow-up, a total of 192 @entity1 developed @entity0 . These cases were followed for additional 7.2  years. Detailed medical records were obtained. We observed an overall positive dose-response relationship between pre-diagnostic hs-CRP and @entity0 risk (hazard ratio (HR)  =  1.06, 95  % CI 1.01-1.11). Postmenopausal @entity1 with above median levels of hs-CRP (>1.2  mg/l) had a 1.42 (95  % CI 1.01-2.00) higher @entity0 risk compared to postmenopausal @entity1 with hs-CRP below median. Postmenopausal @entity1 , who were hormone replacement therapy non-users, and were in the middle tertile (0.8-1.9  mg/l), or highest tertile of hs-CRP (>1.9  mg/l), had a 2.31 (95  % CI 1.31-4.03) and 2.08 (95  % CI 1.16-3.76) higher @entity0 risk, respectively, compared with @entity1 in the lowest tertile. For each unit increase in pre-diagnostic hs-CRP levels (mg/l), we observed an 18  % increase in disease-free interval (95  % CI 0.70-0.97), and a 22  % reduction in overall mortality (95  % CI 0.62-0.98). Our study supports a positive association between pre-diagnostic hs-CRP and @entity0 risk. In contrast, increased pre-diagnostic hs-CRP was associated with improved overall mortality, but our findings are based on a small sample size, and should be interpreted with caution.
